Financials

	2024	2025
Net sales	4.05Cr 4.63Cr 3.73Cr 3.45Cr 6.55Cr 441.56Cr 6.67Cr 45Cr 18Cr 217.3Cr 17Cr 17Cr 751.28Cr	4.11Cr 4.7Cr 3.79Cr 3.5Cr 6.65Cr 448.22Cr 6.77Cr 45Cr 18Cr 220.58Cr 18Cr 17Cr 762.62Cr
Net income	71.55L 81.77L 65.99L 60.99L 1.16Cr 78Cr 1.18Cr 7.9Cr 3.1Cr 38Cr 3.07Cr 3Cr 132.76Cr	47.82L 54.66L 44.11L 40.77L 77.42L 52Cr 78.75L 5.28Cr 2.07Cr 26Cr 2.05Cr 2.01Cr 89Cr
Net Debt	-1.73Cr -1.97Cr -1.59Cr -1.47Cr -2.79Cr -188.16Cr -2.84Cr -19Cr -7.47Cr -93Cr -7.4Cr -7.24Cr -320.14Cr	-2.1Cr -2.4Cr -1.94Cr -1.79Cr -3.41Cr -229.4Cr -3.46Cr -23Cr -9.1Cr -112.9Cr -9.02Cr -8.83Cr -390.32Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	8.68Cr 9.92Cr 8Cr 7.4Cr 14Cr 946.17Cr 14Cr 96Cr 38Cr 465.64Cr 37Cr 36Cr 1.61TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	6.57Cr 7.51Cr 6.06Cr 5.6Cr 11Cr 716.76Cr 11Cr 73Cr 28Cr 352.74Cr 28Cr 28Cr 1.22TCr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI
03/15/03	Eurofins Cerep SA and Jean-Louis Oger, along with the members of the current leadership of Bioaccess, completed the acquisition of a majority stake in Bioaccess S.A.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

10/04	Eurofins Cerep : annonce ses résultats 2025
01/25/01	Eurofins Cerep : Rapport Financier Semestriel - Semestre clos le 30 juin 2025
09/25/09	Eurofins Cerep : Rapport annuel 2024
04/25/04	Eurofins Cerep : annonce ses résultats du 1er semestre 2023
04/25/04	Eurofins Cerep : annonce ses résultats 2024

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.68%	+3.55%	+4.86%	+10.97%	4.94TCr
REVOLUTION MEDICINES, INC.	+0.72%	+1.93%	+424.51%	+624.25%	4.03TCr
IQVIA HOLDINGS INC.	+2.54%	+2.84%	+27.06%	-3.62%	3.4TCr
BEONE MEDICINES AG	+0.31%	+4.16%	+23.87%	+59.76%	3.36TCr
CELLTRION, INC.	-2.09%	-0.80%	+3.56%	+33.56%	2.68TCr
ASCENDIS PHARMA A/S	-0.63%	+2.85%	-	-	1.72TCr
MEDPACE HOLDINGS, INC.	+0.66%	-1.48%	+66.05%	+127.36%	1.52TCr
IONIS PHARMACEUTICALS, INC.	-23.90%	-18.84%	+55.47%	+53.83%	1.4TCr
EUROFINS SCIENTIFIC SE	+2.59%	+0.50%	+15.28%	+21.25%	1.34TCr
Average	+0.66%	+0.83%	+77.58%	+115.92%	2.71TCr
Weighted average by Cap.	+0.77%	+0.90%	+93.37%	+138.87%

End-of-day quote Euronext Paris Other stock markets
- ^EUR	-